KR101893720B1 - 방사 면역 접합체 및 그 용도 - Google Patents

방사 면역 접합체 및 그 용도 Download PDF

Info

Publication number
KR101893720B1
KR101893720B1 KR1020177018914A KR20177018914A KR101893720B1 KR 101893720 B1 KR101893720 B1 KR 101893720B1 KR 1020177018914 A KR1020177018914 A KR 1020177018914A KR 20177018914 A KR20177018914 A KR 20177018914A KR 101893720 B1 KR101893720 B1 KR 101893720B1
Authority
KR
South Korea
Prior art keywords
antibody
cells
seq
conjugate
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177018914A
Other languages
English (en)
Korean (ko)
Other versions
KR20170084349A (ko
Inventor
로이 에이치. 라르센
요슈타인 달
오위빈트 에스. 브루란드
Original Assignee
노르딕 나노벡터 에이에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노르딕 나노벡터 에이에스에이 filed Critical 노르딕 나노벡터 에이에스에이
Publication of KR20170084349A publication Critical patent/KR20170084349A/ko
Application granted granted Critical
Publication of KR101893720B1 publication Critical patent/KR101893720B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177018914A 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도 Expired - Fee Related KR101893720B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29952410P 2010-01-29 2010-01-29
NO20100143 2010-01-29
US61/299,524 2010-01-29
NO20100143A NO331080B1 (no) 2010-01-29 2010-01-29 Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav
PCT/EP2011/051231 WO2011092295A2 (en) 2010-01-29 2011-01-28 Novel radioimmunoconjugates and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127020917A Division KR101758409B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도

Publications (2)

Publication Number Publication Date
KR20170084349A KR20170084349A (ko) 2017-07-19
KR101893720B1 true KR101893720B1 (ko) 2018-08-30

Family

ID=44319900

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177018914A Expired - Fee Related KR101893720B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도
KR1020127020917A Expired - Fee Related KR101758409B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127020917A Expired - Fee Related KR101758409B1 (ko) 2010-01-29 2011-01-28 방사 면역 접합체 및 그 용도

Country Status (25)

Country Link
US (2) US8628749B2 (enExample)
EP (2) EP2705857B1 (enExample)
JP (2) JP5646652B2 (enExample)
KR (2) KR101893720B1 (enExample)
CN (2) CN104338154B (enExample)
AU (1) AU2011209441B2 (enExample)
BR (1) BR112012018843B8 (enExample)
CA (1) CA2786655C (enExample)
DK (2) DK2705857T3 (enExample)
ES (2) ES2469140T3 (enExample)
HR (1) HRP20140538T1 (enExample)
IL (2) IL221091A (enExample)
MX (2) MX342539B (enExample)
NO (1) NO331080B1 (enExample)
NZ (1) NZ601055A (enExample)
PH (2) PH12012501516A1 (enExample)
PL (1) PL2528627T3 (enExample)
PT (1) PT2528627E (enExample)
RS (1) RS53346B (enExample)
RU (2) RU2560587C9 (enExample)
SG (1) SG182685A1 (enExample)
SI (1) SI2528627T1 (enExample)
UA (1) UA108631C2 (enExample)
WO (1) WO2011092295A2 (enExample)
ZA (1) ZA201205007B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203372A1 (en) * 2011-12-13 2015-10-30 Nordic Nanovector Asa Chimeric therapeutic anti - cd37 antibodie hh1
US20150093397A1 (en) * 2012-03-30 2015-04-02 Immunogen, Inc. Methods for Increasing Efficacy of CD37-Based Therapy
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
EP3332813B1 (en) * 2013-06-07 2019-05-29 Nordic Nanovector ASA Combination therapy comprising anti-cd20 antibody and the radiolabeled hh1 monoclonal antibody
AU2014296219A1 (en) 2013-08-01 2016-02-25 Agensys, Inc. Antibody drug conjugates (ADC) that bind to CD37 proteins
BR112017020689A2 (en) * 2015-04-07 2018-06-26 Memorial Sloan-Kettering Cancer Center nanoparticulate immunoconjugates
GB201600328D0 (en) * 2016-01-08 2016-02-24 Univ Oslo Hf Anti-CD37 chimeric antigen receptors and immune cells expressing them
JP2019529433A (ja) * 2016-09-16 2019-10-17 ノルディック ナノベクター アルメン アクスイェ セルスカプ リロトマブおよび１７７Ｌｕ‐リロトマブ・サテトラキセタンを用いた非ホジキンリンパ腫の治療方法
KR102406510B1 (ko) 2017-07-03 2022-06-10 현대자동차주식회사 연료전지 시스템용 수소 공급 방법
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
US20210106703A1 (en) * 2017-11-22 2021-04-15 Nordic Nanovector Asa Radioimmunoconjugates in combination with other drugs as treatment against nhl
CA3137568A1 (en) * 2019-04-25 2020-10-29 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases
CN117241832A (zh) * 2021-03-19 2023-12-15 海德堡医药研究有限责任公司 B淋巴细胞特异性的鹅膏毒素抗体缀合物
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
US20250333531A1 (en) 2021-10-06 2025-10-30 Nordic Nanovector Asa Humanized hh1
CN114081969A (zh) * 2021-11-23 2022-02-25 成都纽瑞特医疗科技股份有限公司 标记的小分子抗体、及其标记方法和应用
CN117285631A (zh) * 2023-11-24 2023-12-26 原子高科股份有限公司 用于放射性免疫治疗的Lu-177标记MUC1抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
MXPA02010507A (es) * 2000-04-25 2003-05-14 Idec Pharma Corp Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central.
RU2005122033A (ru) * 2002-12-13 2006-01-27 Митра Медикал Текнолоджи Аб (Se) Направленные противолимфомные средства с эффекторной и аффиновой функциями, связанные трехфункциональным реагентом
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP1587550B1 (en) * 2003-01-31 2011-07-27 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
HUE026303T2 (hu) * 2005-07-25 2016-06-28 Emergent Product Dev Seattle B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Labelled Compounds and Radiopharmaceuticals, 39(12), 1039-1046, 1997.

Also Published As

Publication number Publication date
HK1179157A1 (en) 2013-09-27
PH12017501038B1 (en) 2019-02-22
PL2528627T3 (pl) 2014-08-29
IL221091A0 (en) 2012-09-24
US9358309B2 (en) 2016-06-07
JP5855209B2 (ja) 2016-02-09
EP2705857A2 (en) 2014-03-12
PT2528627E (pt) 2014-06-12
HRP20140538T1 (hr) 2014-07-18
US20120301396A1 (en) 2012-11-29
RU2560587C9 (ru) 2015-11-27
KR101758409B1 (ko) 2017-07-14
RU2664475C1 (ru) 2018-08-17
SG182685A1 (en) 2012-08-30
CN102762230A (zh) 2012-10-31
PH12012501516A1 (en) 2024-04-03
EP2705857B1 (en) 2016-06-22
BR112012018843B8 (pt) 2020-12-22
JP2013518086A (ja) 2013-05-20
CA2786655A1 (en) 2011-08-04
BR112012018843B1 (pt) 2020-09-24
EP2528627B1 (en) 2014-03-19
NO331080B1 (no) 2011-09-26
SI2528627T1 (sl) 2014-08-29
KR20130028051A (ko) 2013-03-18
NZ601055A (en) 2013-12-20
RU2560587C2 (ru) 2015-08-20
US20140147384A1 (en) 2014-05-29
EP2528627A2 (en) 2012-12-05
JP2015057415A (ja) 2015-03-26
EP2705857A3 (en) 2014-07-30
BR112012018843A2 (pt) 2017-10-17
CA2786655C (en) 2016-12-13
ES2469140T3 (es) 2014-06-17
CN104338154A (zh) 2015-02-11
IL237507A0 (en) 2015-04-30
AU2011209441B2 (en) 2016-03-03
CN102762230B (zh) 2014-08-13
PH12017501038A1 (en) 2017-12-11
JP5646652B2 (ja) 2014-12-24
BR112012018843A8 (pt) 2017-12-19
IL221091A (en) 2015-03-31
CN104338154B (zh) 2017-09-22
RS53346B (sr) 2014-10-31
US8628749B2 (en) 2014-01-14
AU2011209441A1 (en) 2012-07-19
ES2592402T3 (es) 2016-11-30
MX2012008695A (es) 2012-11-23
WO2011092295A3 (en) 2011-11-24
DK2528627T3 (da) 2014-05-12
HK1195736A1 (en) 2014-11-21
DK2705857T3 (en) 2016-08-29
NO20100143A1 (no) 2011-08-01
MX342539B (es) 2016-10-04
RU2012135430A (ru) 2014-03-10
WO2011092295A2 (en) 2011-08-04
ZA201205007B (en) 2013-09-25
UA108631C2 (xx) 2015-05-25
KR20170084349A (ko) 2017-07-19

Similar Documents

Publication Publication Date Title
KR101893720B1 (ko) 방사 면역 접합체 및 그 용도
KR102033819B1 (ko) 상향조절 항원 발현 방법
JP2024519970A (ja) 三価放射性同位体生物標的放射性医薬品、調製方法及び使用
Wojdowska et al. Standardization of Procedures for the Preparation of 177Lu-and 90Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
Rousseau et al. Radiolabeled Antibodies for Cancer Radioimmunotherapy
HK1195736B (en) Radioimmunoconjugates and their use
HK1179157B (en) Radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20230825

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230825

St.27 status event code: N-4-6-H10-H13-oth-PC1903